Dr. Snyder's research relates to the broad field of Transfusion Medicine and, more specifically, Transfusion Oncology and Transfusion Immunobiology. His current research includes an on-going evaluation of new pathogen reduction technology for reduction of pathogens in red cells, platelets and plasma. This technology includes the addition of various compounds to blood to inactivate known, as well as unknown, viral, bacterial, and protozoal contaminants in donated blood. The laboratory has a special expertise in conducting Phase III trials for transfusion of pathogen-reduced blood components into patients. We are also involved in ongoing evaluations of clinical responses of patients to pheresis interventions for a variety of immunologic disorders.
Specialized Terms: Health and Medicine; Membranes; Metabolism; Apheresis Technology; Pathogen Inactivation; Platelet Apoptosis; Platelet Storage Lesion Manufacturing Tissue Engineered Vascular Grafts for Pediatric Surgical Patients
We are conducting 2 Phase III RCTs for pathogen reduced RBCs. One involves patients undergoing complex cardiovascular surgery (ReCePI) and the other anemic oncology patients receiving simple transfusions (RedeS).
Blood Banks; Blood Transfusion; Membranes; Metabolism; Medical Laboratory Science; Organisms; Chemicals and Drugs
| Conditions | Study Title |
|---|---|
| Diseases of the Cardiovascular System | Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients (ReCePI) |